Final analysis identifies patients with triple negative breast cancer (TNBC) as the key target...
Featured articles
Its drug Anavex2-73 is being developed to treat Rett Syndrome, a rare neurological disorder that...
Liberum analyst Yuan Low says it is still early on in graphene’s development, but he has “no...
Successful registration with the DEA by its partner Transdermal cracks the door to begin formula...
The small-cap biotech appears to have addressed any need for a deep-pocketed partner while it...
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
Featured companies
IXICO is dedicated to delivering insights in neuroscience. The company's mission is to transfo...
Sphere Medical is a dynamic company specialising in the development of innovative medical moni...
Futura Medical is a pharmaceutical group that develops innovative products for both the prescr...
Redx Pharma was formed in 2010 and is an established drug discovery and development company ba...
Arix Bioscience is a global healthcare and life science company that drives value in private a...
Callitas Health Inc: (OTCQB: MPHMF) OTC & Pharma R&D company focused on sexual wellnes...
Global biotech Newswire
Final analysis identifies patients with triple negative breast cancer (TNBC) as the key target...
Its drug Anavex2-73 is being developed to treat Rett Syndrome, a rare neurological disorder that...
Liberum analyst Yuan Low says it is still early on in graphene’s development, but he has “no...
Successful registration with the DEA by its partner Transdermal cracks the door to begin formula...
The small-cap biotech appears to have addressed any need for a deep-pocketed partner while it...
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
For the first nine months of 2018, the businesses Essentra is looking to exit made an operating...
The acquisition provides Dechra with a “strategically important presence” in Brazil, the fourth...
As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln,...
Executive video interviews
Faz Chowdhury, chief executive of Nemaura Medical Inc (NASDAQ:NMRD), spoke to Proactive...
Aethlon Medical Inc (NASDAQ:AEMD) CEO Jim Joyce spoke with Proactive Investor's...
Berlin Cures Holding AG President Joannes Müller and COO Peter Göttel sit down with...
Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine...
Bryan Oronsky and James Brown from EpicentRx sit down with Christine Corrado at the BIO...
ChemioCare USA Inc CEO Pedro Lichtinger sits down with Proactive Investors' Christine...
Epygen Group President Debayan Ghosh sits down with Christine Corrado at the BIO...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive...
Michael Hunt, CFO at Reneuron Plc (LON:RENE), spoke to Proactive ahead of new data being...
Veravas CEO John Forrest sits down with Proactive Investors' Christine Corrado at the...
Dr. Reddy’s Laboratories Ltd (NYSE:RDY) Senior Vice President Anil Namboodiripad spoke...
Heidelberg Pharma AG (ETR:WL6) CEO Jan Schmidt-Brand spoke with Christine Corrado at the...
Big picture investment ideas in Biotech Capital
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO...
The broker says the cancer treatment developer could potentially take the entire share of the...
In its recent half-year results, the medical research investor recorded a loss after tax of...
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX...
WideCells has undertaken a review of the business to deliver a strategy that will generate...
The pharma group expects to dose the first patient in the Phase III trial of its MED2002...
The drug developer had originally to recruit 80 people for the second part of its phase II study...
Capital Network Research
Avacta Group - Maximising Affimer's potential across therapeutics and...
October 03 2018
Over the last year or so, management has delivered significant progress in bringing their...
Judges Scientific PLC - 2018 Interim Results
September 21 2018
Judges Scientific reported results for the first half of 2018. The period included a...
Legendary Investments - Hidden value potential
September 03 2018
Legendary Investments (LON:LEG) creates value through privately held and pre-market...
Avacta Group - Exciting partnership with Bach BioSciences
July 30 2018
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with...
Avacta Group - Rapid Progress of Immuno-oncology Programs
April 16 2018
KEY INVESTOR MESSAGES
Faster than expected development of the second immuno-oncology...
Summit Therapeutics Plc - Stock Valuation Undemanding
April 03 2018
- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne...
Partners:
